Alleh Lindquist At Benzinga Cannabis Capital Conference Says We We Have Clear Pathways With The FDA Today And Regulations And How We Would Go And About Getting Either A Drug Approved Following In The Footsteps Of Epidiolex
Portfolio Pulse from Benzinga Newsdesk
Lindquist, speaking at the Benzinga Cannabis Capital Conference, stated that there are clear pathways with the FDA today regarding regulations and the process of getting a drug approved, following in the footsteps of Epidiolex.
September 27, 2023 | 3:19 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
The discussion at the Benzinga Cannabis Capital Conference about clear FDA pathways for drug approval may impact MSOS, an ETF that tracks the performance of US-listed companies in the cannabis industry.
The news does not directly mention any specific actions or decisions related to MSOS. However, as an ETF that tracks US-listed cannabis companies, any regulatory changes or clarifications regarding FDA drug approval pathways could potentially impact the companies in its portfolio, and therefore the ETF itself.
CONFIDENCE 70
IMPORTANCE 50
RELEVANCE 50